Currently, there are no accurate and simple methods available to measure this risk of atrophy in patients treated with topical glucocorticosteroids. In the present clinical trial, we validated a new score (Dermaphot(®) score) to assess the atrophogenic potential of glucocorticosteroids. 36 healthy adult volunteers were included in an investigator-initiated, blinded, randomized, intra-individual comparison, vehicle controlled multi-centre study. Subjects were treated in a randomized manner for 3 weeks with pimecrolimus cream 1 %, mometasone furoate (1 mg/g), clobetasol propionate 0.05 % and vehicle. In addition, ultrasound examination for skin thickness was performed. Data demonstrated a direct correlation of the achieved Dermaphot(®) score and the ultrasound thickness measurements. Our study shows that the Dermaphot(®) score can be used as a simple method to evaluate the atrophogenic potential of glucocorticosteroids. Respectively, we showed that the new score is an easy, valid and sensitive new tool for early detecting and quantifying even subclinical glucocorticosteroid-induced skin damage. We demonstrated that the score is able to differentiate the extent of skin atrophy (damage) after 3 weeks of topical glucocorticosteroid application with different levels of skin transparency and levels of telangiectasia.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s00403-012-1297-2 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Six-month Rituximab-Lenalidomide regimen in advanced untreated Follicular Lymphoma: SAKK 35/10 Trial 10-year Update.
Blood Adv
January 2025
Ente Ospedaliero Cantonale, Switzerland.
The Swiss Group for Clinical Cancer Research (SAKK) and the Nordic Lymphoma Group (NLG) conducted the SAKK 35/10 randomized phase-2 trial (NCT0137605) to compare rituximab (R) alone versus R plus lenalidomide (L) as initial treatment for follicular lymphoma (FL). Patients with grade 1-3a FL, requiring systemic therapy, were randomized to either R (n=77; 375 mg/m2 IV x 1, weeks 1-4) or RL (n=77; R on the same schedule and L at 15 mg daily continuously). Responders (evaluated at 10 weeks) repeated R during weeks 12-15 with or without L (for a total of 18 weeks).
View Article and Find Full Text PDFCo-Designing a Digital Brief Intervention to Reduce the Risk of Prescription Opioid-Related Harm Among People With Chronic Noncancer Pain: Qualitative Analysis of Patient Lived Experiences.
JMIR Form Res
January 2025
Faculty of Medicine, The University of Queensland, Brisbane, Australia.
Background: Opioid medications are important for pain management, but many patients progress to unsafe medication use. With few personalized and accessible behavioral treatment options to reduce potential opioid-related harm, new and innovative patient-centered approaches are urgently needed to fill this gap.
Objective: This study involved the first phase of co-designing a digital brief intervention to reduce the risk of opioid-related harm by investigating the lived experience of chronic noncancer pain (CNCP) in treatment-seeking patients, with a particular focus on opioid therapy experiences.
Risk Factors for Gastrointestinal Bleeding in Patients With Acute Myocardial Infarction: Multicenter Retrospective Cohort Study.
J Med Internet Res
January 2025
Department of Gastroenterology, Affiliated Hospital of Guangdong Medical University, Zhanjiang, China.
Background: Gastrointestinal bleeding (GIB) is a severe and potentially life-threatening complication in patients with acute myocardial infarction (AMI), significantly affecting prognosis during hospitalization. Early identification of high-risk patients is essential to reduce complications, improve outcomes, and guide clinical decision-making.
Objective: This study aimed to develop and validate a machine learning (ML)-based model for predicting in-hospital GIB in patients with AMI, identify key risk factors, and evaluate the clinical applicability of the model for risk stratification and decision support.
Predicting the risk of bone metastases in patients with newly diagnosed prostate cancer - Development and validation of a nomogram model.
PLoS One
January 2025
Institute of Translational Medicine, Medical College, Yangzhou University, Yangzhou, Jiangsu, PR. China.
Objectives: The aim of this study was to develop and validate a nomogram model that predicts the risk of bone metastasis (BM) in a prostate cancer (PCa) population.
Methods: We retrospectively collected and analyzed the clinical data of patients with pathologic diagnosis of PCa from January 1, 2013 to December 31, 2022 in two hospitals in Yangzhou, China. Patients from the Affiliated Hospital of Yangzhou University were divided into a training set and patients from the Affiliated Clinical College of Traditional Chinese Medicine of Yangzhou University were divided into a validation set.
Possible influence of sex on the relationship between dual-task gait costs and cognitive decline in older adults.
PLoS One
January 2025
Institute of Physiotherapy, FH Joanneum University of Applied Sciences, Graz, Austria.
The impact of cognitive decline in older adults can be evaluated with dual-task gait (DTG) testing in which a cognitive task is performed during walking, leading to increased costs of gait. Previous research demonstrated that higher DTG costs correlate with increasing cognitive deficits and with age. The present study was conducted to explore whether the relationship between the DTG costs and cognitive abilities in older individuals is influenced by sex differences.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!